Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Utidelone + Capecitabine Adjuvant Therapy in Non-pCR TNBC
NCT06385990Phase 2Recruiting
- Sponsor
- Hunan Cancer Hospital
- Start
- Mar 2024
- Primary completion
- Mar 2025
- Modality
- Allosteric Modulators
- Countries
- 1
01
Overview
A Phase 2 trial of utidelone in triple-negative breast cancer (TNBC), sponsored by Hunan Cancer Hospital. Started Mar 2024; status: recruiting.
02
Drugs
utidelone
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT06385990.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06385990.